People who have been buying lower-cost, compounded versions of the popular weight-loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide) from compounding pharmacies may find their access changing. The U.S. Food and Drug Administration has moved to restrict the compounding of these GLP-1 (glucagon-like peptide-1) medicines now that the manufacturer shortages that once justified widespread compounding have resolved. The shift has raised questions about the safety, cost and availability of compounded GLP-1 products, and it is better described as a tightening of the rules than a single outright ban.
What the FDA Actions Actually Do
Compounding pharmacies prepare customized versions of medicines, and federal rules generally allow them to produce copies of an approved drug when that drug is in short supply. Semaglutide and tirzepatide spent long stretches on the FDA shortage list, which opened the door to large-scale compounding. After the FDA declared those shortages resolved in 2025, the legal basis for making copies narrowed sharply. The agency has since escalated in stages: in September 2025 it issued more than 55 warning letters to online sellers over misleading direct-to-consumer marketing of compounded GLP-1 drugs; in February 2026 it announced steps to restrict the GLP-1 active pharmaceutical ingredients still flowing into non-approved compounded products; and on April 30, 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the “503B bulks list,” concluding there was no clinical need for outsourcing facilities to compound them from bulk substances. The public comment period on that proposal closed on June 29, 2026.
How Compounded Medicines Work
U.S. compounding falls into two categories. A 503A pharmacy makes small batches to meet an individual patient’s prescription — for example, a specific concentration or a formulation that removes an allergen. A 503B “outsourcing facility” can make larger volumes under stricter manufacturing standards. Both expanded their GLP-1 output during the shortage, and the FDA’s proposals and enforcement are aimed largely at the high-volume production that the shortage had permitted, rather than at individualized compounding for genuine clinical needs.
The Additives Question
Some compounders marketed customized GLP-1 formulations that included extra ingredients, such as B vitamins promoted as reducing the nausea and gastrointestinal side effects common with GLP-1 drugs, or levocarnitine promoted as helping counter muscle loss. Pharmacy experts have cautioned that the benefits of such additives are largely theoretical, because they have not been established in safety or efficacy trials. The combinations also fall outside the testing that supported the approved branded products.
Safety Concerns
Safety worries around compounded GLP-1 products are not hypothetical. In July 2024 the FDA alerted providers, compounders and patients to dosing errors with compounded injectable semaglutide, warning that people unfamiliar with drawing medicine from a vial and converting between milligrams, milliliters and “units” had in some cases administered five to twenty times the intended dose. Reported adverse events ranged from nausea and vomiting to fainting, dehydration, acute pancreatitis and gallstones, with some cases requiring hospitalization. Unlike brand-name GLP-1 injections, which come in pre-filled pens, many compounded versions are supplied in vials with separate syringes, which increases the room for measurement mistakes.
Cost and Access
Cost is central to the debate, because compounded versions were often far cheaper than brand-name drugs, and advocates for compounding have urged the FDA not to over-correct in ways that cut off access for patients who rely on these medicines. The commercial landscape is also shifting: in March 2026 Novo Nordisk and the telehealth company Hims & Hers resolved a dispute and agreed that Hims would offer Novo Nordisk’s branded semaglutide products while winding down most marketing of compounded GLP-1s. Novo Nordisk, for its part, has filed numerous lawsuits against sellers of unapproved compounded “semaglutide,” and courts have issued dozens of injunctions. List prices for newer oral options and manufacturer direct-to-consumer programs vary widely, and many insured patients still face meaningful out-of-pocket costs, according to survey data on GLP-1 users.
Limitations and What to Watch
This is a fast-moving regulatory situation, and several points deserve caution. The 503B bulks-list exclusion was a proposal open for public comment through late June 2026; final rules, enforcement timing and any legal challenges could change how strictly the restrictions apply. “Ban” is a simplification — individualized 503A compounding for documented clinical needs may continue in some circumstances even as mass production of copies is curtailed. Pricing figures and program terms change frequently and vary by insurance, so current costs should be confirmed directly with providers and manufacturers. Most importantly, this article is a general explainer and not medical advice; anyone taking or considering a compounded or branded GLP-1 drug should consult a licensed clinician before making changes. Authoritative, current information is available from the FDA’s compounding safety communications, with ongoing legal and industry analysis from outlets such as Pharmacy Times.
